---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-116754"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:57:54.906638+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# Theriva reports Q3 2023 cash of $31.2M, VCN-01 trial on track for H1 2024 enrollment completion

## Summary
- Cash and equivalents $31.2M as of Sept 30, 2023; expected runway into Q1 2025.
- R&D expense $4.0M in Q3 2023, up 56% from $2.6M YoY, driven by VCN-01 clinical costs.
- VIRAGE Phase 2b trial of VCN-01 in metastatic PDAC remains on track to complete enrollment in H1 2024.
- Meeting with FDA before year-end to discuss VCN-01 development pathway for pediatric retinoblastoma.
- SYN-004 Phase 1b/2a trial in HCT recipients on track for second cohort enrollment in H1 2024.

## SEC filing metadata
- accession: 0001104659-23-116754
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465923116754/0001104659-23-116754-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465923116754/tm2330262d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-116754
- JSON: https://secwatch.observer/filing/0001104659-23-116754.json
- Plain text: https://secwatch.observer/filing/0001104659-23-116754.txt

## Key facts
- Earnings Releases
  Theriva Biologics, Inc. reported financial results for third quarter ended September 30, 2023.
  - Period: third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 13, 2023, Theriva Biologics, Inc., a Nevada corporation (the “Registrant”) issued a press release that included financial information for its quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/894158/000110465923116754/0001104659-23-116754-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.